189 related articles for article (PubMed ID: 11528571)
1. A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993.
Christie CD; Garrison KM; Kiely L; Gupta RK; Heubi J; Marchant CD
Clin Infect Dis; 2001 Oct; 33(7):997-1003. PubMed ID: 11528571
[TBL] [Abstract][Full Text] [Related]
2. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
[TBL] [Abstract][Full Text] [Related]
3. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
4. Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).
Ward JI; Cherry JD; Chang SJ; Partridge S; Keitel W; Edwards K; Lee M; Treanor J; Greenberg DP; Barenkamp S; Bernstein DI; Edelman R;
Clin Infect Dis; 2006 Jul; 43(2):151-7. PubMed ID: 16779740
[TBL] [Abstract][Full Text] [Related]
5. Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.
Le T; Cherry JD; Chang SJ; Knoll MD; Lee ML; Barenkamp S; Bernstein D; Edelman R; Edwards KM; Greenberg D; Keitel W; Treanor J; Ward JI;
J Infect Dis; 2004 Aug; 190(3):535-44. PubMed ID: 15243929
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.
Knuf M; Zepp F; Meyer C; Grzegowski E; Wolter J; Riffelmann M; Wirsing von König CH
Vaccine; 2006 Mar; 24(12):2043-8. PubMed ID: 16356597
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of an acellular pertussis vaccine among adolescents and adults.
Ward JI; Cherry JD; Chang SJ; Partridge S; Lee H; Treanor J; Greenberg DP; Keitel W; Barenkamp S; Bernstein DI; Edelman R; Edwards K;
N Engl J Med; 2005 Oct; 353(15):1555-63. PubMed ID: 16221778
[TBL] [Abstract][Full Text] [Related]
8. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Chan SH; Tan PT; Han HH; Bock HL
Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
[TBL] [Abstract][Full Text] [Related]
10. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
[TBL] [Abstract][Full Text] [Related]
11. Japanese clinical trials with Takeda acellular pertussis vaccine.
Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
[TBL] [Abstract][Full Text] [Related]
12. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content.
Hendrikx LH; Berbers GA; Veenhoven RH; Sanders EA; Buisman AM
Vaccine; 2009 Nov; 27(47):6530-6. PubMed ID: 19729085
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and sensitivity of ELISA IgG pertussis antitoxin after infection and vaccination with Bordetella pertussis in young children.
Hallander HO; Ljungman M; Storsaeter J; Gustafsson L
APMIS; 2009 Nov; 117(11):797-807. PubMed ID: 19845530
[TBL] [Abstract][Full Text] [Related]
14. [Pertussis seroprevalence and vaccination status in three selected provinces of Turkey].
Kurtoğlu D; Gözalan A; Cöplü N; Miyamura K; Ishida S; Morita M; Akin L; Esen B
Mikrobiyol Bul; 2008 Jul; 42(3):389-98. PubMed ID: 18822881
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of the Biken acellular pertussis vaccine in adults with or without previous vaccination against pertussis in childhood.
Knuf M; Schmitt HJ; Mohnike K; Zepp F; Habermehl P; Kampmann C; Herden P
Med Klin (Munich); 2004 Sep; 99(9):495-9. PubMed ID: 15372178
[TBL] [Abstract][Full Text] [Related]
16. A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization.
Keitel WA; Muenz LR; Decker MD; Englund JA; Mink CM; Blumberg DA; Edwards KM
J Infect Dis; 1999 Aug; 180(2):397-403. PubMed ID: 10395855
[TBL] [Abstract][Full Text] [Related]
17. Effect of injection site on reactogenicity and immunogenicity of acellular and whole-cell pertussis component diphtheria-tetanus-pertussis vaccines in infants.
Tapiainen T; Cherry JD; Heininger U
Vaccine; 2005 Oct; 23(43):5106-12. PubMed ID: 16023771
[TBL] [Abstract][Full Text] [Related]
18. Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults--a review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Thierry-Carstensen B; Dalby T; Stevner MA; Robbins JB; Schneerson R; Trollfors B
Vaccine; 2013 Oct; 31(45):5178-91. PubMed ID: 23994021
[TBL] [Abstract][Full Text] [Related]
19. Clinical trials of acellular pertussis vaccine in Sweden. An attempt to solve the problem of pertussis vaccination.
Olin P
Ann Sclavo Collana Monogr; 1986; 3(1-2):165-72. PubMed ID: 2892504
[No Abstract] [Full Text] [Related]
20. [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults].
Abarca K; Valdivieso F; Potin M; Ibáñez I; Vial P
Rev Med Chil; 2002 May; 130(5):502-10. PubMed ID: 12143270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
